IN
Item 9 Labs Corp.
INLB · OTC
$0.00 +0.00% (+$0.00)
Market Cap $70.2K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.00x
P/S 0.00x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 102.51%
Rev. growth 63.98%
FCF growth N/A
Profitability
13 /100
Weak Op. margin 106.01%
Gross margin 33.61%
FCF margin 35.45%
Quality
3 /100
Poor Asset turnover 0.20x
ROIC 25.60%
ROA 28.12%
Debt
61 /100
Moderate Int. coverage -3.86x
Debt/Equity 0.45x
Net debt/EBITDA -1.22x
Stability
1 /100
Unstable EPS volatility 85.31%
Beta 0.14x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INLB
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jeffrey I. Rassas
Employees
97
Headquarters
Phoenix
Upcoming events
02 DEC
Earnings
Upcoming earnings report